Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 4, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial performance data.
Material Changes
The only material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("GSK Trust"). On March 2, 2004, Abacus (GSK) Trustees Limited transferred 7,510 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—are interested in the shares held in the trust in the same manner as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust following the transfer of 7,510 shares.
- Confirm the specific allocation of the transferred shares among the three named directors versus other plan participants.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions.